The Dana-Farber Cancer Institute is an NCI-designated Comprehensive Cancer Center and, as such, has supported an integrated and balanced program of basic and clinical cancer research from its inception. The basic research program has been focused on cancer- relevant studies in retrovirology, human immunobiology, pharmacology, and cellular and molecular biology. Much of this research is conducted with animal and cell culture models which have been effectively adapted for studies of the biology of HIV, anti-viral chemotherapy, and AIDS immunology. The Institute thus was well prepared to respond to the earliest NIH-sponsored research initiatives in AIDS. Although the Institute now has an extensive commitment to AIDS research supported by a variety of federal, private, and institutional mechanisms, the present application is designed to provide a coordinated administrative and scientific mechanism which will. 1. enhance existing investigator-initiated research; 2. promote collaboration and interaction among Institute investigators; and 3. facilitate the development of innovative AIDS research approaches. In this manner, the Institute intends to organize its existing AIDS research activities into a focused, multidisciplinary, effort for examining the biology of HIV and for developing immunologic and pharmacologic approaches for AIDS prevention and therapy. It is planned that established investigators within the Institute's research programs will form a collaborative, interactive, group outside of traditional Institute divisional lines and will apply their expertise and technology to these objectives. Certain existing Institute core facilities will be expanded for this purpose but it will be necessary to establish additional research cores and administrative support to effectively pursue these objectives. Support is requested in the present application to expand the Institute's Biohazard Containment, Molecular Biology, and Pharmacology core facilities and to establish Animal Biohazard, Animal Production, Baculovirus Culture and Hybridoma core facilities.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Liu, Songtao; Fleysher, Roman; Fleysher, Lazar et al. (2010) Brain metabolites B1-corrected proton T1 mapping in the rhesus macaque at 3 T. Magn Reson Med 63:865-71
Liu, Songtao; Gonen, Oded; Fleysher, Roman et al. (2009) Metabolite proton T(2) mapping in the healthy rhesus macaque brain at 3 T. Magn Reson Med 62:1292-9
Ratai, Eva-Maria; Pilkenton, Sarah J; Greco, Jane B et al. (2009) In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain. BMC Neurosci 10:63
Gonen, Oded; Liu, Songtao; Goelman, Gadi et al. (2008) Proton MR spectroscopic imaging of rhesus macaque brain in vivo at 7T. Magn Reson Med 59:692-9
Ratai, Eva-Maria; Hancu, Ileana; Blezek, Daniel J et al. (2008) Automatic repositioning of MRSI voxels in longitudinal studies: impact on reproducibility of metabolite concentration measurements. J Magn Reson Imaging 27:1188-93
Liu, Songtao; Gonen, Oded; Fleysher, Lazar et al. (2008) Regional metabolite T2 in the healthy rhesus macaque brain at 7T. Magn Reson Med 59:1165-9
Li, Xing; Gold, Bert; O'hUigin, Colm et al. (2007) Unique features of TRIM5alpha among closely related human TRIM family members. Virology 360:419-33
Javanbakht, Hassan; An, Ping; Gold, Bert et al. (2006) Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 354:15-27
Diaz-Griffero, Felipe; Li, Xing; Javanbakht, Hassan et al. (2006) Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 349:300-15
Gonzalez, R Gilberto; Greco, Jane B; He, Julian et al. (2006) New insights into the neuroimmunity of SIV infection by magnetic resonance spectroscopy. J Neuroimmune Pharmacol 1:152-9

Showing the most recent 10 out of 205 publications